SRZNW · Surrozen, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on SRZNW. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About SRZNW · Surrozen, Inc.
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Live Quote
HOLD (score -1) · 12-1 mom -14.1% · RSI 0 · below_both · -14.1% from high
Targets blend Wall Street consensus (? analysts: low — / mean — / high —) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Surrozen is an early-stage biotech with Wnt-signaling therapeutics for ophthalmic conditions; SRZNW is its redeemable warrant (each warrants exercisable for 1/15 share of common stock). The investigation trigger was met — 4 Form 4 filings on May 13-14, 2026 from directors receiving option grants at $30.14 strike and executives vesting RSUs with subsequent sell-to-cover — but these are NOT open-market purchases (P code) that signal insider conviction at current price levels. SRZNW trades at ~$0.025, an effective exercise-implied share price of ~$0.38 vs a common stock price of approximately $0.25-0.35; the warrant is deeply out-of-the-money with no realistic path to in-the-money given the biotech's burn rate and stage of development. No options chain exists. The company has $106.9M cash, which provides runway but not a near-term catalyst sufficient to bridge a 1,000x price gap on SRZNW.